Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis
Pooled result · Pain alleviation (main analysis: 25 RCTs, 2856 patients)Result — go to the resultSMD −0.35 95% CI −0.48 to −0.22Authors' conclusion
Strong evidence supports the efficacy and safety of collagen derivatives for osteoarthritis treatment.
Study context
- Population
- Patients with OA in randomized controlled trials (RCTs) of collagen derivatives (PubMed, Embase, Cochrane Library searched till June 2023)
- Participants
- 3,165 patients35 RCTs
- Comparison
- Collagen derivatives vs control
- Outcome
- Primary outcome (not named in the abstract); main analysis based on 25 RCTs, 2856 patients
Methodological detailstrial sequential analysis, random-effects, frequentist framework, RoB 2, GRADE, Trial sequential analyses indicated sufficient statistical power
- Trial sequential analysis
- Random-effects
- Frequentist framework
- RoB 2
- GRADE
- Trial sequential analyses indicated sufficient statistical power
Pooled result
As reported in the abstract
Pain alleviation (main analysis: 25 RCTs, 2856 patients)
SMD
−0.35
95% CI −0.48 to −0.22
Collagen derivativesvs Control
SMD −0.35 (95% CI −0.48 to −0.22)
Further pooled results
| Outcome | SMD (95% CI) | |
|---|---|---|
| Function improvementHigh certainty | −0.31 (−0.41 to −0.22) | |
| −0.6−0.4−0.200.2Difference (linear scale) |
Safety
- Did not increase the risk of withdrawal or adverse events vs control
Original publication
Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis. Osteoarthritis Cartilage. Published 11 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →